Proving the Concept: A Sampler of Early-Stage Science at AACR 2025
The AACR 2025 meeting presented early-stage clinical data on an off‑the‑shelf CAR‑NK therapy (SENTI‑202) for acute myeloid leukemia (AML) and a novel anti‑CCR8 antibody (CHS‑114) for head and neck squamous cell carcinoma (HNSCC). Both agents demonstrated encouraging early efficacy and safety signals in phase 1 studies. Additionally, an antibody‑drug conjugate (MICVO) targeting the extracellular matrix marker EDB+FN showed preclinical activity across multiple solid tumor models.
The AACR 2025 meeting presented early-stage clinical data on an off‑the‑shelf CAR‑NK therapy (SENTI‑202) for acute myeloid leukemia (AML) and a novel anti‑CCR8 antibody (CHS‑114) for head and neck squamous cell carcinoma (HNSCC). Both agents demonstrated encouraging early efficacy and safety signals in phase 1 studies. Additionally, an antibody‑drug conjugate (MICVO) targeting the extracellular matrix marker EDB+FN showed preclinical activity across multiple solid tumor models.
These findings underscore the potential of next‑generation immuno‑cellular and targeted‑xenograft therapies to address unmet needs in aggressive hematologic malignancies and refractory solid tumors.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability